Clinical trial
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
NCT02974153 · Alder Biopharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT02974153 |
|---|---|
| Title | Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine |
| Official title | A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine |
| Acronym | PROMISE 2 |
| Lead sponsor | Alder Biopharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Migraine Disorders |
| Intervention type | Biological |
| Interventions | ALD403 (Eptinezumab), Placebo |
| Enrollment | 1,121 |
| Start date | Nov 1, 2016 |
| Primary completion | Nov 1, 2017 |
| Completion | Apr 1, 2018 |
| First posted | Nov 28, 2016 |
| Last update posted | Jun 9, 2020 |
| Countries | Belgium, Czechia, Denmark, Georgia, Germany, Hungary, Italy, Russia, Slovakia, Spain, Ukraine, United Kingdom and 1 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: